| Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2184 | 2017 |
| Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review L Degenhardt, A Peacock, S Colledge, J Leung, J Grebely, P Vickerman, ... The Lancet Global Health 5 (12), e1192-e1207, 2017 | 1491 | 2017 |
| Epidemiology and natural history of HCV infection B Hajarizadeh, J Grebely, GJ Dore Nature reviews Gastroenterology & hepatology 10 (9), 553-562, 2013 | 1342 | 2013 |
| Global statistics on alcohol, tobacco and illicit drug use: 2017 status report A Peacock, J Leung, S Larney, S Colledge, M Hickman, J Rehm, ... Addiction 113 (10), 1905-1926, 2018 | 1115 | 2018 |
| Global patterns of opioid use and dependence: harms to populations, interventions, and future action L Degenhardt, J Grebely, J Stone, M Hickman, P Vickerman, ... The Lancet 394 (10208), 1560-1579, 2019 | 652 | 2019 |
| Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale‐up in the age of direct‐acting antivirals NK Martin, P Vickerman, J Grebely, M Hellard, SJ Hutchinson, VD Lima, ... Hepatology 58 (5), 1598-1609, 2013 | 608 | 2013 |
| Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression R Waziry, B Hajarizadeh, J Grebely, J Amin, M Law, M Danta, J George, ... Journal of hepatology 67 (6), 1204-1212, 2017 | 539 | 2017 |
| The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection J Grebely, K Page, R Sacks‐Davis, MS van der Loeff, TM Rice, J Bruneau, ... Hepatology 59 (1), 109-120, 2014 | 520 | 2014 |
| Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States S Barua, R Greenwald, J Grebely, GJ Dore, T Swan, LE Taylor Annals of internal medicine 163 (3), 215-223, 2015 | 501 | 2015 |
| Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review S Larney, A Peacock, J Leung, S Colledge, M Hickman, P Vickerman, ... The Lancet Global Health 5 (12), e1208-e1220, 2017 | 475 | 2017 |
| Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study S Blach, NA Terrault, F Tacke, I Gamkrelidze, A Craxi, J Tanaka, I Waked, ... The Lancet Gastroenterology & Hepatology 7 (5), 396-415, 2022 | 438 | 2022 |
| Elbasvir–grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial GJ Dore, F Altice, AH Litwin, O Dalgard, EJ Gane, O Shibolet, ... Annals of internal medicine 165 (9), 625-634, 2016 | 432 | 2016 |
| Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis EJ Aspinall, S Corson, JS Doyle, J Grebely, SJ Hutchinson, GJ Dore, ... Clinical Infectious Diseases 57 (suppl_2), S80-S89, 2013 | 399 | 2013 |
| Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis T Santo, B Clark, M Hickman, J Grebely, G Campbell, L Sordo, A Chen, ... JAMA psychiatry 78 (9), 979-993, 2021 | 376 | 2021 |
| Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ... The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018 | 323 | 2018 |
| Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine J Grebely, M Prins, M Hellard, AL Cox, WO Osburn, G Lauer, K Page, ... The Lancet infectious diseases 12 (5), 408-414, 2012 | 275 | 2012 |
| Global, regional, and country‐level estimates of hepatitis C infection among people who have recently injected drugs J Grebely, S Larney, A Peacock, S Colledge, J Leung, M Hickman, ... Addiction 114 (1), 150-166, 2019 | 261 | 2019 |
| Potential role for Interleukin‐28B genotype in treatment decision‐making in recent hepatitis C virus infection J Grebely, K Petoumenos, M Hellard, GV Matthews, V Suppiah, ... Hepatology 52 (4), 1216-1224, 2010 | 248 | 2010 |
| Barriers associated with the treatment of hepatitis C virus infection among illicit drug users J Grebely, KA Genoway, JD Raffa, G Dhadwal, T Rajan, G Showler, ... Drug and alcohol dependence 93 (1-2), 141-147, 2008 | 246 | 2008 |
| Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis B Hajarizadeh, EB Cunningham, H Reid, M Law, GJ Dore, J Grebely The lancet Gastroenterology & hepatology 3 (11), 754-767, 2018 | 233 | 2018 |
